All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
In a letter to the editor of Leukemia, published in March 2017, Hermann Einsele and colleagues from the Julius-Maximilians-University of Würzburg present the case for the use of bortezomib as consolidation therapy for newly diagnosed multiple myeloma (MM) patients, following autologous stem cell transplantation (ASCT). Data were analyzed from two bortezomib phase 3 trials that assessed NDMM patients after ASCT, and stratified according to age and prior treatment regimens. Studies were carried out in 47 departments across Germany, between October 2006 and May 2013. The primary endpoint was progression free survival (PFS) from the start of induction therapy. Secondary endpoints assessed were event-free survival (EFS), from start of induction to start of new chemotherapy or death, response rates, overall survival (OS), quality of life, and safety.
Consolidation therapy with bortezomib (administered over a period of 5 months, 4 cycles), was well-tolerated and highly effective in delaying disease progression (6-month increase in PFS), as well as improving the quality of response in NDMM patients. Of note, improvements were seen in high-risk subsets: < VGPR after HDT/ASCT, del13q, t[4;14] or del17p, and, t(4;14), del 17p for which prognosis is generally low. In addition, a favorable response was independent of prior bortezomib treatment in the induction therapy.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox